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MaOBJECTIVES The authors sought to understand the clinical and angiographic outcomes of dissections left after
drug-coated balloon (DCB) angioplasty.
BACKGROUND Second-generation DCB may be an alternative to stents in selected populations for the treatment of
native coronary lesions. However, the use of these devices may be hampered by a certain risk of acute vessel recoil or
residual coronary dissection. Moreover, stenting after DCB has shown limited efﬁcacy. Little is known about when a non–
ﬂow-limiting dissection is left after DCB angioplasty.
METHODS Thiswas a prospective observational studywhose aimwas to investigate the outcome of a consecutive series of
patientswithnative coronary artery disease treatedwith second-generationDCBand residual coronary dissection at 2 Italian
centers.Weevaluatedpatient clinical conditions at 1 and9months, and angiographic followupwas undertaken at 6months.
RESULTS Between July2012and July2014, 156patientswere treatedwithDCB for native coronary artery disease. Fifty-two
patients had a ﬁnal dissection, 4 of which underwent prosthesis implantation and 48 were left untreated and underwent
angiographic follow-up after 201 days (interquartile range: 161 to 250 days). The dissections were all type A to C, and none
determined an impaired distal ﬂow. Complete vessel healing at angiography was observed in 45 patients (93.8%), whereas
3 patients had persistent but uncomplicated dissections, and 3 had binary restenosis (6.2%). Late lumen loss was 0.14 mm
(0.14 to 0.42). Major adverse cardiovascular events occurred in 11 patients in the entire cohort and in 4 of the dissection
cohort (7.2%vs.8.1%;p¼0.48).Weobserved8and3 target lesion revascularizations, respectively (5.3%vs.6.2%;p¼0.37).
CONCLUSIONS In this cohort of consecutive patients treated with new-generation DCB and left with a ﬁnal dissection,
this strategy of revascularization seemed associated with the sealing of most of dissections and without signiﬁcant neo-
intimal hyperplasia. (J Am Coll Cardiol Intv 2015;8:2003–9) © 2015 by the American College of Cardiology Foundation.D rug-coated balloons (DCB)weredeveloped toovercome neointimal hyperplasia and havebeen widely tested for the treatment of in-
stent restenosis, inwhich setting theyhave shownanef-
ﬁcacy comparable to drug-eluting stents (DES) in terms
of target lesion revascularization (TLR) (1–4). For this
indication, DCB gained a Class I, Level of Evidence:
A in the latest European Society of Cardiology and
the European Association for Cardio-Thoracic Surgery
guidelines for myocardial revascularization (5).
However, from the mechanical point of view, DCB
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Very preliminary observations seem to show how
new-generation DCB could be associated with a
faster spontaneous healing of an arterial dissection
left after balloon angioplasty, especially in case of
angioplasties of the femoropopliteal region and for
the treatment of in-stent restenosis (6,7). The aim
of this study was to test this hypothesis in a
consecutive series of patients with native coronary
vessel disease.ac Department, University Medical Center Utrecht,
cone, Palermo, Italy. The authors have reported that
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TABLE 1 Patients’
Age, yrs
Female
Hypertension
Hypercholesterolemia
Diabetes
Prior MI
Prior revascularization
Multivessel coronary
Stable angina
Unstable angina
Non–ST-segment
elevation MI
Culprit vessel
Left anterior desce
artery
Left circumﬂex arte
Right coronary arte
Values are median (inte
signiﬁcance.
DCB ¼ drug-coated ba
ABBR EV I A T I ON S
AND ACRONYMS
DCB = drug-coated balloon(s)
DES = drug-eluting stent(s)
LLL = late lumen loss
MACE = major adverse cardiac
event(s)
MLD = minimal lumen diameter
PCI = percutaneous coronary
intervention
RVD = reference vessel
diameter
TLR = target lesion
revascularization
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2004METHODS
This is an observational study conducted at 2
centers expert in DCB angioplasty. The aim of
the study was to investigate the outcome of
consecutive coronary dissections left after
DCB angioplasty in native vessels.SEE PAGE 2010Inclusion criterion was any percutaneous
coronary intervention (PCI) performed with
DCB in native coronary vessels. Exclusion
criteria were any use of DCB for reasons
different from the aforementioned (e.g., forin-stent restenosis); ST-segment elevation myocar-
dial infarction that occurred in the previous 48 h; or
life expectancy <1 year. Other clinical indications for
PCI, unstable hemodynamics at presentation, and the
presence of renal insufﬁciency were not exclusion
criteria. We had a restrictive use of DCB in case of big
vessel size (e.g., >3 mm in diameter) or in case of very
calciﬁc vessels, especially when we feared possible
vessel recoil.
In the current study, the following devices were
used: Restore (Cardionovum, Milano, Italy) and Elu-
tax SV (Aachen Resonance, Lainate, Italy) DCB. These
2 devices, both eluting paclitaxel, may be considered
a second-generation DCB because of a more efﬁcientClinical Characteristics
All DCB
Population,
Native Vessels
(N ¼ 156)
No
Dissection
Cohort
(n ¼ 104)
Dissection
Cohort
(n ¼ 52) p Value
61 (54–67) 59 (51–64) 60 (54–66) 0.18
50 (32.0) 31 (29.8) 19 (36.5) 0.31
91 (58.3) 59 (56.7) 32 (63.5) 0.21
95 (60.9) 65 (62.5) 30 (57.7) 0.32
55 (35.2) 37 (35.6) 18 (34.6) 0.86
14 (9.3) 10 (9.6) 4 (8.4) 0.48
17 (10.9) 9 (8.7) 8 (13.5) 0.16
disease 78 (50) 52 (50) 26 (50) 0.91
82 (52.6) 55 (52.9) 27 (51.9) 0.84
31 (19.9) 19 (18.3) 12 (23.0) 0.33
43 (27.6) 30 (28.8) 13 (25) 0.75
nding 88 (56.4) 52 (50) 35 (67.0) 0.02
ry 13 (8.3) 10 (9.6) 3 (5.8) 0.06
ry 55 (35.2) 42 (40.4) 14 (26.9) 0.842
rquartile range) or n (%). p Value in bold have reached statistical
lloon; MI ¼ myocardial infarction.delivery of paclitaxel to the vessel wall, which results
in a longer persistence of the drug. Restore DCB has a
concentration of paclitaxel of 3.0 mg/mm2 of balloon
surface, and shellac is used as a carrier. Elutax SV DCB
has a concentration of paclitaxel of 2.2 mg/mm2 of
balloon surface, and is embedded in a 3-layer matrix.
Available measures for both devices used in this
study included diameters of 2.0, 2.5, and 3.0 mm, and
lengths of 15, 20, 25, and 30 mm.
The intervention was performed according to in-
ternational guidelines and the recent Italian position
paper on DCB PCI (8). Speciﬁcally, pre-dilation with an
undersized semicompliant balloon was mandatory
(the recommended size was 0.9:1 of DCB). In case of
ﬂow-limiting dissection after pre-dilation, we recom-
mended considering conversion to a stent PCI without
using a DCB. The DCB was inﬂated for 30 to 45 s at
nominal pressure, according to the morphological
characteristics of the lesion (e.g., degree of calciﬁca-
tion, length, tortuosity). After DCB use, ﬁnal assess-
ment was undertaken after at least 5 min, in order to
catch early vessel recoil. In this event, bailout stent
implantation was considered. The type of stent or
scaffold was left to the operator’s discretion.
Patients with any residual coronary dissection after
DCB use entered the current analysis. It is our habit
not to stent coronary dissections of type A to C
(National Heart, Lung, and Blood Institute [NHBLI]
classiﬁcation system for intimal tears, developed by
the Coronary Angioplasty Registry) with Thrombol-
ysis In Myocardial Infarction (TIMI) ﬂow grade 3. In
case of coronary dissections of type D or higher and/
or impaired distal ﬂow, it is our habit to implant a
stent.
After sheath insertion, all patients were adminis-
tered unfractionated heparin (single bolus of 5,000
IU, then adjunctive boluses following activated clot-
ting time) or bivalirudin (bolus of 0.75 mg/kg fol-
lowed by an infusion of 1.75 mg/kg/h for the duration
of the procedure). A bailout glycoprotein IIb/IIIa re-
ceptor inhibitor strategy was allowed in case of high
thrombus burden. All patients received aspirin (either
100 mg/day for at least 3 days before PCI or with a pre-
PCI 300-mg intravenous bolus), and clopidogrel (300
or 600 mg as a loading dose, followed by 75 mg daily)
or prasugrel (60 mg as a loading dose, followed by 10
mg daily) or ticagrelor (180 mg as a loading dose,
followed by 90 mg twice a day) following clinical
indication. The duration of prescribed dual anti-
platelet treatment was 1 month, or 6 months in case of
stent implantation; after this time, patients were
prescribed only aspirin.
Angiographic success was deﬁned as a ﬁnal resid-
ual stenosis <50% by visual estimate, with TIMI ﬂow
TABLE 2 Procedural Characteristics
All DCB
Population, Native
Vessels
(N ¼ 156)
No
Dissection
Cohort
(n ¼ 104)
Dissection
Cohort
(n ¼ 52) p Value
Radial approach 144 (92.3) 96 (92.3) 48 (92.3) 0.95
Total occlusion 18 (11.5) 9 (8.7) 9 (17.3) 0.47
Reference vessel
diameter, mm
2.83 (2.12–3.01) 2.87 (2.15–3.0) 2.80 (2.07–2.97) 0.21
Minimal lumen diameter, mm 0.4 (0.0–0.73) 0.37 (0.03–0.65) 0.41 (0.00–0.79) 0.11
Stenosis severity, % 83 (72–100) 82 (71–100) 84 (70–100) 0.18
Lesion length, mm 21 (10–33) 19 (10–28) 22 (12–33) 0.10
Severe-moderate calciﬁcation
(visual estimation)
100 (64.1) 60 (57.7) 40 (76.9) 0.01
Pre-dilation balloon
diameter, mm
2.45 (2.0–3.0) 2.35 (2.0–3.0) 2.5 (2.0–3.0) 0.04
DCB diameter, mm 2.55 (2.0–3.0) 2.50 (2.0–3.0) 2.60 (2.0–3.0) 0.035
DCB length, mm 25 (15–30) 24 (15–30) 25 (15–30) 0.37
Max pressure during DCB
angioplasty, atm
12 (8–14) 11 (9–14) 12 (8–15) 0.49
DCB inﬂation duration, s 35 (30–45) 37 (32–45) 34 (30–42) 0.33
OCT/IVUS guidance 15 (9.6) 11 (10.6) 4 (7.7) 0.13
Minimal lumen diameter
after PCI, mm
2.21 (1.75–2.67) 2.17 (1.75–2.58) 2.24 (1.84–2.67) 0.22
Procedural success 156 (100) 104 (100) 52 (100) 0.87
Periprocedural myocardial
infarction
21 (13.5) 13 (12.5) 8 (15.4) 0.42
Bivalirudin 15 (9.6) 9 (8.7) 6 (11.5) 0.23
Dual antiplatelet therapy
ASA þ clopidogrel 130 (83.3) 85 (81.7) 45 (86.5) 0.24
ASA þ ticagrelor/prasugrel 26 (16.7) 19 (18.3) 7 (13.5) 0.36
Values are n (%) or median (interquartile range). Values in bold have reached statistical signiﬁcance.
ASA ¼ acetylsalicylic acid; DCB ¼ drug-coated balloon; IVUS ¼ intravascular ultrasound; OCT ¼ optical
coherence tomography; PCI ¼ percutaneous coronary intervention.
TABLE 3 Angiographic Follow-Up of Patients With Dissection
After DCB PCI
Dissection Cohort
(n ¼ 48)
Reference vessel diameter, mm 2.87 (2.11 to 2.98)
Minimal lumen diameter, mm 2.42 (2.22 to 2.66)
Diameter stenosis, % 12 (8 to 20)
LLL, mm 0.14 (0.14 to 0.42)
Complete vessel healing 45 (93.8)
Binary restenosis 3 (6.2)
Values are median (interquartile range) or n (%). Follow-up was at 201 days
(interquartile range 161 to 250 days).
LLL ¼ late lumen loss; other abbreviations as in Table 2.
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2005grade 3. Procedural success was deﬁned as angio-
graphic success without the occurrence of in-hospital
major adverse cardiac events (MACE) (deﬁned as any
occurrence of ST-segment elevation acute myocardial
infarction, target vessel revascularization, TLR, or
death). Periprocedural myocardial infarction was
deﬁned as a post-procedural increase in cardiac
troponin T >5  99th percentile of the upper refer-
ence limit.
All patients underwent clinical follow-up after 1 and
9 months; all patients in the dissection cohort under-
went angiographic follow-up with quantitative coro-
nary assessment after 6 months, in order to assess
the degree of coronary dissection healing. All mea-
surements were performed on cineangiograms recor-
ded after 200 mg of intracoronary nitroglycerin
administration. Identical projections were used for
each comparison. Quantitative analysis of angio-
graphic data were initially assessed by a single expe-
rienced investigator, and afterwards validated by an
internal committee of experts, using the CAAS II
research system (Pie Medical Imaging, Maastricht,
the Netherlands). The following parameters were
analyzed: reference vessel diameter (RVD), minimal
lumen diameter (MLD), percent diameter stenosis (the
difference between RVD and MLD divided by RVD),
late lumen loss (LLL) (deﬁned as the difference be-
tween MLD after index PCI and MLD at angiographic
follow up), lesion length, binary restenosis, and
persistence of dissection (NHBLI classiﬁcation). Mea-
surements included the whole segment treated plus
5 mm proximally and distally. Binary restenosis was
deﬁned as stenosis of at least 50% of the luminal
diameter at angiographic follow-up.
Primary endpoint of this study was the percentage
of dissection healing detected at angiographic follow-
up. Secondary endpoints included TLR, binary reste-
nosis, LLL, and the occurrence of MACE.
Data are presented as mean  SD or median (inter-
quartile range) as appropriate for continuous vari-
ables, and as proportions (%) for dichotomous
variables. The differences between groups were
assessed by chi-square test or Fisher exact test for
categorical data, and paired Student t test for contin-
uous data. The relative risk and its 95% conﬁdence
interval were calculated for each study endpoint. A 2-
sided p value <0.05 was considered statistically
signiﬁcant.
RESULTS
The study population consisted of 156 consecutive
patients treated between July 2012 and July 2014 at
2 centers with second-generation DCB for nativecoronary artery disease (87 with Restore and 69 with
Elutax SV), that were prospectively entered in the
database. Thirty-ﬁve percent of patients had dia-
betes, and clinical indication was stable angina in 82,
unstable angina in 31, and non–ST-segment elevation
myocardial infarction in 43 patients. Procedural suc-
cess was achieved in all patients.
FIGURE 1 MLD Before DCB PCI, After DCB PCI, and at
Angiographic Follow-Up in Patients Left With a Dissection
Notably, there was a diffuse lumen enlargement at angiographic
control. DCB ¼ drug-coated balloon; MLD ¼ minimal lumen
diameter; PCI ¼ percutaneous coronary intervention.
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2006For the purpose of this analysis, we studied the
52 patients that had an angiographically detectable
dissection after DCB angioplasty. All patients of this
cohort underwent programmed coronary angiog-
raphy after 6 to 9 months. Baseline clinical charac-
teristics and clinical indication to PCI of the entire
population and of the 2 cohorts are shown in Table 1.
The dissection study group did not differ signiﬁ-
cantly from the entire DCB group, if we exclude a
higher incidence of left anterior descending artery as
the culprit vessel, the degree of calciﬁcation of the
culprit lesion, the size of balloon used for pre-
dilation, and the size of the DCB (Table 2). Baseline
angiographic characteristics are shown in Table 2.
Of note, the vessel diameter was 2.83 mm in the
entire population, and 2.80 mm in the dissection
population.
Of the 52 patients with residual dissection after
DCB PCI, 4 had a prosthesis implanted (2 a bare-metal
stent, 1 a DES, and 1 a biovascular scaffold). The
reason for implanting a stent/scaffold was impair-
ment of distal ﬂow in 3 patients, and the presence of a
spiral, type D dissection in 1.
All patients with a ﬁnal dissection underwent
scheduled angiographic follow-up with quantitative
coronary assessment, that was undertaken after 201
days (interquartile range 161 to 250 days). Angio-
graphic outcome is presented in Table 3. Of note, LLL
was as low as 0.14  0.28 mm in this group. We also
observed a late lumen enlargement in the treated
segments (Figure 1).Complete vessel healing at angiography was
observed in 45 of 48 patients (93.8%) (Figure 2). The 3
patients that had an unhealed dissection had,
respectively, a type A, type B, and type C coronary
dissection after the index PCI. TLR occurred in 3 pa-
tients (6.2%) in the dissection cohort and in 8 patients
(5.3%) in the entire DCB population (p ¼ 0.49)
(Figure 3). Of the 3 patients that underwent TLR in the
dissection cohort, the ﬁrst 2 had recurrence of angina
after 4 and 6 months, respectively; angiography
showed subocclusive coronary stenoses (of 85% and
90%, respectively) at the site of the previous PCI that
were successfully treated with DES implantation. The
third patient was asymptomatic but had a persisting,
chronic coronary dissection discovered at angio-
graphic follow-up that was sealed with DES
implantation.
The other clinical endpoints showed no signiﬁcant
differences between the whole group and the
groups with and without dissection (Figure 3). In-
terestingly, we did not observe cases of target vessel
myocardial infarction during the entire clinical
follow-up (average length 9  3 months). Finally,
there were no signiﬁcant differences between the 2
devices tested in terms of clinical and angiographic
endpoints.
DISCUSSION
This prospective observational study describes the
ﬁrst consecutive series of patients treatedwith DCB for
native coronary artery disease and with ﬁnal dissec-
tion left “unsealed” with prosthesis. Our results
conﬁrm that leaving a non–ﬂow-limiting dissection
untreated after DCB PCI is safe and not associated with
an increase in myocardial infarction and TLR, despite
the short-term (1 month) dual antiplatelet treatment.
Notably, we did not observe a correlation between the
type of dissection at baseline (type A, B, or C) and the
propensity to healing (Figure 4).
DCB were developed to overcome neointimal hy-
perplasia and have been ﬁrst tested in the in-stent
restenosis setting with good results maintained for
years (3,9). However, the use of DCB for the treatment
of native vessels seems particularly encouraging,
especially in the case of small vessels and distal
lesions, where the encumbrance of a stent may limit
its potential and is associated with increased rates
of restenosis and stent thrombosis. However, the
application of this technology as standalone proce-
dure in de novo lesions has resulted in conﬂicting
results. After some early mistakes, such as the ones
depicted in the PICCOLETO (Paclitaxel-Eluting
Balloon Versus Paclitaxel-Eluting Stent in Small
FIGURE 2 Angiographic Outcome of Dissections Left After DCB Angioplasty
A and B show the ﬁnal dissections (respectively, a type C and a long type A dissection, red circles); after 6 months, both dissections were
healed (C and D). DCB ¼ drug-coated balloon.
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2007Coronary Artery Diseases) study (10,11), a newer
generation of DCB has been tested in the BELLO
(Balloon Elution and Late Loss Optimization) study
for the treatment of native coronary vessels. Here,
DCB overcame Taxus DES for the treatment of small
vessel disease in terms of the primary endpoint of LLL
(0.08  0.38 mm vs. 0.29  0.44 mm; 95% conﬁdence
interval: 0.34 to 0.09; p ¼ 0.001) (12). Recently, the
2-year follow up of the BELLO study, that showed
persisting good results of DCB in terms of clinical
endpoints, has been published. (13) Similar encour-
aging results for this technology in native coronary
vessels were shown in large registries with different,
new-generation DCB (14,15).
This study was performed with 2 devices of the
latest available technology, that provides optimal
paclitaxel delivery to the vessel wall and contempo-
rarily allows its longer persistence.
The central point of our ﬁndings is the safety of
leaving a dissection after DCB angioplasty. Earlyexperiences have shown how leaving a dissection
after plain old balloon angioplasty was associated
with increased rates of thrombotic events, early
reocclusion, and recurrence of restenosis, and this
was one of the main indications for the use of
stents in an earlier era (16). The widespread use of
more potent antiplatelet regimens (e.g., the associ-
ation of aspirin with a P2Y12 receptor inhibitor) has
undoubtedly improved the early outcome of this
type of patient. In the early stent era, a previous
series of patients treated consecutively with plain
angioplasty and with a ﬁnal dissection, despite a
very low occurrence of thrombotic events and an
acceptable rate of restenosis (12%), 36.7% of dis-
sections left were still visible at 6-month angio-
graphic follow-up (17). With this current study, we
have opened the hypothesis that the effect of
paclitaxel, when correctly delivered to the vessel
wall, may have a role in facilitating the healing of
coronary vessels.
FIGURE 3 Clinical Follow-Up After 9 Months in the Entire Population and in the
Dissection and No-Dissection Cohorts
p Values are not signiﬁcant for all comparisons. DCB ¼ drug-coated balloon; MACE ¼major
cardiovascular event(s); MI ¼ myocardial infarction; TLR ¼ target lesion revascularization;
TV ¼ target vessel.
FIGURE 4 The Fate of Dissections After DCB Angioplasty
Figure shows what happened to dissections at 6-month angiography: 45 were healed and 3
were chronic. Therewas not an apparent correlation between the type of initial dissection left
after DCB angioplasty and its fate. We followed the NHLBI classiﬁcation for coronary dis-
sections. DCB ¼ drug-coated balloon; NHLBI ¼ National Heart, Lung, and Blood Institute.
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2008This effect was already described in a post-hoc
analysis of the THUNDER (Local Taxan With Short
Time Contact for Reduction of Restenosis in Distal
Arteries) study (6), where patients with femo-
ropopliteal disease were randomized to simple an-
gioplasty or DCB. In this analysis, patients treated
with DCB resulting in ﬁnal dissection of any grade
had signiﬁcantly lower LLL than patients with
dissection after simple angioplasty (0.4 vs. 1.9 mm;
p ¼ 0.001), especially if the dissection grade was se-
vere (type C to E) (0.4 vs 2.4 mm; p ¼ 0.05). This
result was maintained for all the duration of the
2-year follow-up, with a TLR of 10% versus 56%
respectively (p ¼ 0.002) (6). In another study, Agos-
toni et al. (18) have found how leaving small dissec-
tions after DCB angioplasty for in-stent restenosis
resulted in complete dissection healing at optical
coherence tomography after 6 months. In addition to
this information, we also found that our patients,
who did not have a “caged” coronary artery because
they did not have in-stent restenosis, also had an
improved late lumen gain, as already described in
another series of patients treated with DCB for
native coronary vessel disease (19). This late lumen
enlargement (Figure 1) is another interesting effect
of DCB that needs further, dedicated analysis.
In this study, we decided to limit the degree of
dissections left to a low-medium grade (type A to C)
because of ethical reasons (the eventual vessel oc-
clusion would result in myocardial infarction). Now
with our results, if the dissection is of low-medium
grade, it seems safe to leave it untreated. In fact,
data from the literature show how any stent
strategy associated with DCB use is unsafe or yields
unsatisfactory results (20,21). There are some initial
data on the use of DES after DCB, but such data are
limited in number and are without angiographic
follow-up (22), thus the contemporary use of 2
different antirestenotic drugs with stent metal layers
needs to be better understood before recommending
this strategy. Moreover, in this case, the advantages
of using a DCB are immediately lost (23).
STUDY LIMITATIONS. First, the population is limited
and derives from 2 centers expert in this type of PCI,
thus itmay not be reproducible everywherewithout an
adequate learning curve. Moreover, we have to
disclose an initial bias at the time of decision of leaving
the dissection untreated. So far, these results are not
easily reproducible in all settings. Our ﬁndings,
although a conﬁrmation of other previous studies, are
the ﬁrst assessment of this property of new-generation
DCB in native coronary lesions, and need to be vali-
dated in other ad hoc clinical studies.
PERSPECTIVES
WHAT IS KNOWN? DCB are a useful tool for the treatment of
small coronary arteries. However, little is known regarding the
fate of dissections left unsealed after DCB PCI.
WHAT IS NEW? With this study, for the ﬁrst time in the
coronary tree, we showed a pro-healing effect of DCB when
a ﬁnal dissection was left at the end of PCI.
WHAT IS NEXT? We now need an adequately powered study
(e.g., a randomized controlled study) to test this preliminary
report in a broader population of coronary artery disease patients.
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2009CONCLUSIONS
In a consecutive series of patients treated with new-
generation DCB for native coronary artery disease
and with a ﬁnal non–ﬂow-limiting dissection, these
lesions tended to heal despite their initial severity.
After DCB angioplasty, a strategy of bailout stenting
should be reserved to more severe, ﬂow-limiting
dissections.
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